CAS 936563-96-1

General Information

Ibrutinib is an orally administered anticancer drug for the treatment of mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL) and Waldenstrm’s macroglobulinemia (WM ‘ also known as lymphoplasmacytic lymphoma).

About the API

Trade name(s) Imbruvica
Technology Synthetic
Therapeutic category Oncology
Available formulations Oral Solid
Regulations US DMF Flag US DMF